Mechanistic studies showed that the immunodominant PSMA459 epitope becomes cysteinylated under normal physiologic conditions, and this cysteinylated form of PSMA459 inhibits the CD4+ T cell recognition of prostate cancer cells. Here, CD4 is linked to prostate carcinoma.